share_log

Capricor Therapeutics (NASDAQ:CAPR) Releases Earnings Results, Misses Estimates By $0.04 EPS

Capricor Therapeutics (NASDAQ:CAPR) Releases Earnings Results, Misses Estimates By $0.04 EPS

卡布里科治療公司(納斯達克代碼：CAPR)公佈收益業績，低於預期0.04美元每股收益
kopsource ·  2022/08/12 05:21

Capricor Therapeutics (NASDAQ:CAPR – Get Rating) issued its earnings results on Wednesday. The biotechnology company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.04), Fidelity Earnings reports. During the same period last year, the firm earned ($0.21) EPS.

凱旋治療公司(納斯達克代碼：CAPR-GET Rating)週三發佈了財報。富達收益報告顯示，這家生物技術公司本季度每股收益為0.29美元，低於分析師普遍預期的每股0.25美元和0.04美元。去年同期，該公司每股收益為0.21美元。

Capricor Therapeutics Stock Performance

Capricor Treateutics股票表現

CAPR traded up $0.76 during trading on Thursday, hitting $5.28. The stock had a trading volume of 569,778 shares, compared to its average volume of 229,072. Capricor Therapeutics has a twelve month low of $2.56 and a twelve month high of $5.85. The stock has a 50 day simple moving average of $4.23 and a two-hundred day simple moving average of $3.96. The company has a market capitalization of $128.43 million, a PE ratio of -5.50 and a beta of 5.00.

在週四的交易中，CAPR的交易價格上漲了0.76美元，達到5.28美元。該股成交量為569,778股，而其平均成交量為229,072股。Capricor Treateutics的12個月低點為2.56美元，12個月高位為5.85美元。該股的50日簡單移動均線切入位為4.23美元，200日簡單移動均線切入位為3.96美元。該公司市值為1.2843億美元，市盈率為-5.50，貝塔係數為5.00。

Get
到達
Capricor Therapeutics
卡布裏卡治療公司
alerts:
警報：

Analyst Upgrades and Downgrades

分析師升級和下調評級

Separately, StockNews.com raised shares of Capricor Therapeutics to a "sell" rating in a research report on Monday, May 23rd.

另外，StockNews.com在5月23日星期一的一份研究報告中將Capricor Treateutics的股票評級上調至“賣出”。

Insider Transactions at Capricor Therapeutics

Capricor Treateutics的內幕交易

In related news, Director David B. Musket sold 28,215 shares of the firm's stock in a transaction on Wednesday, June 29th. The shares were sold at an average price of $3.77, for a total transaction of $106,370.55. Following the completion of the transaction, the director now owns 12,747 shares of the company's stock, valued at $48,056.19. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director David B. Musket sold 17,775 shares of the business's stock in a transaction dated Monday, June 27th. The shares were sold at an average price of $4.44, for a total transaction of $78,921.00. Following the transaction, the director now directly owns 40,962 shares in the company, valued at $181,871.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David B. Musket sold 28,215 shares of the business's stock in a transaction dated Wednesday, June 29th. The shares were sold at an average price of $3.77, for a total transaction of $106,370.55. Following the completion of the transaction, the director now owns 12,747 shares in the company, valued at $48,056.19. The disclosure for this sale can be found here. Insiders own 9.00% of the company's stock.
在相關新聞中，董事大衞·B·馬斯基特在6月29日星期三的一次交易中出售了28,215股該公司股票。這些股票的平均價格為3.77美元，總成交金額為106,370.55美元。交易完成後，董事現在擁有該公司12,747股股票，價值48,056.19美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可以在美國證券交易委員會的網站上看到。在相關新聞中，董事大衞·B·馬科特在一筆日期為6月27日(星期一)的交易中出售了17,775股該公司股票。這些股票以4.44美元的平均價格出售，總成交額為78,921.00美元。交易完成後，董事現在直接擁有該公司40,962股股份，價值181,871.28美元。這筆交易是在提交給美國證券交易委員會(Securities&Exchange Commission)的一份文件中披露的，可以通過這個超級鏈接訪問。此外，在一筆日期為6月29日(星期三)的交易中，董事大衞·B·馬科特出售了28,215股該公司股票。這些股票的平均價格為3.77美元，總成交金額為106,370.55美元。交易完成後，董事現在擁有該公司12,747股，價值48,056.19美元。此次拍賣的披露信息可在此處找到。內部人士持有該公司9.00%的股份。

Hedge Funds Weigh In On Capricor Therapeutics

對衝基金對Capricor Treeutics的看法

Institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in shares of Capricor Therapeutics by 5.6% in the 1st quarter. Vanguard Group Inc. now owns 1,020,998 shares of the biotechnology company's stock valued at $3,502,000 after acquiring an additional 54,260 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Capricor Therapeutics by 54.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 148,768 shares of the biotechnology company's stock valued at $510,000 after acquiring an additional 52,611 shares during the period. State Street Corp raised its stake in shares of Capricor Therapeutics by 10.4% in the 1st quarter. State Street Corp now owns 79,224 shares of the biotechnology company's stock valued at $272,000 after acquiring an additional 7,476 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Capricor Therapeutics by 38.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 42,238 shares of the biotechnology company's stock valued at $145,000 after acquiring an additional 11,821 shares during the period. Finally, UBS Group AG raised its stake in shares of Capricor Therapeutics by 326.0% in the 2nd quarter. UBS Group AG now owns 29,352 shares of the biotechnology company's stock valued at $102,000 after acquiring an additional 22,462 shares during the period. 9.49% of the stock is currently owned by institutional investors and hedge funds.

機構投資者和對衝基金最近買賣了該公司的股票。先鋒集團(Vanguard Group Inc.)在第一季度增持了Capricor Treeutics 5.6%的股份。先鋒集團目前持有這家生物技術公司1,020,998股股票，價值3,502,000美元，在此期間又購入了54,260股。Dimension Fund Advisors LP在第一季度將其在Capricor Treateutics的股份增加了54.7%。Dimension Fund Advisors LP現在擁有這家生物技術公司148,768股股票，價值51萬美元，在此期間又購買了52,611股。道富集團在第一季度增持了Capricor Treateutics 10.4%的股份。道富集團目前擁有79,224股這家生物技術公司的股票，價值27.2萬美元，在此期間又購買了7,476股。高盛股份有限公司在第一季度增持了卡布里科治療公司38.9%的股份。高盛股份有限公司在此期間增持了11,821股，目前持有這家生物技術公司42,238股股票，價值145,000美元。最後，瑞銀集團在第二季度增持了326.0%的Capricor Treateutics股票。瑞銀集團(UBS Group AG)在此期間增持了22,462股，現在擁有29,352股這家生物技術公司的股票，價值102,000美元。9.49%的股票目前由機構投資者和對衝基金持有。

Capricor Therapeutics Company Profile

Capricor治療公司簡介

(Get Rating)

(獲取評級)

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

卡布里科治療公司(納斯達克代碼：CAPR)是一家臨牀階段的生物技術公司，專注於治療罕見疾病的一流生物療法的發現、開發和商業化。Capricor的主要候選藥物CAP-1002是一種異基因細胞療法，目前正在臨牀開發中，用於治療Duchenne肌營養不良症。

Featured Articles

專題文章

  • Get a free copy of the StockNews.com research report on Capricor Therapeutics (CAPR)
  • Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
  • Find and Profitably Trade Stocks at 52-Week Lows
  • Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
  • 3 Stable Growth Stocks for Bumpy Times
  • Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
  • 免費獲取StockNews.com關於Capricor治療(CAPR)的研究報告
  • 迪士尼(NYSE：DIS)的股票剛剛給了投資者一個巨大的信號
  • 找到並獲利於52周低點的股票交易
  • 清潔能源法案通過後，太陽能股大放異彩
  • 顛簸時代的3只穩定成長股
  • 大型和小型石油和天然氣類股盈利後反彈

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

接受《Capricor Treateutics Daily》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Capricor Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論